DELTAVIEW MODEL

by Riverain Technologies  · Based in United States → — Artificial Intelligence. Real Results. Shaping the Future of Cardiothoracic Health.
Oncology Pulmonology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

The DELTAVIEW MODEL, originally developed by Riverain Medical Group (now Riverain Technologies), was an early AI-driven medical imaging software. It was specifically designed for the temporal comparison of current and prior chest X-ray images to aid in the detection of subtle changes, such as emerging or enlarging lung nodules that may indicate early-stage lung cancer. The software utilized bone suppression technology to provide a clearer view of soft tissues by electronically removing ribs and clavicles from the radiograph. By aligning and registering two patient images, DELTAVIEW produced a third subtraction image, accentuating differences and making changes more conspicuous for radiologists. This technology was a precursor to Riverain Technologies’ current ClearRead™ suite, which continues to leverage advanced AI and patented suppression technologies to improve diagnostic accuracy and efficiency in cardiothoracic imaging.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Temporal comparison of chest X-rays
  • Bone suppression technology
  • Generation of subtraction images to highlight changes
  • Detection of emerging or enlarging lung nodules
  • Identification of early-stage lung cancer
  • Seamless integration with PACS
  • Improved sensitivity for actionable solitary pulmonary nodules
  • Aids in detection of soft tissue interval changes

Use Cases

  • Early detection of lung cancer
  • Monitoring patients with chronic obstructive pulmonary disease (COPD)
  • Monitoring patients with chronic pleural thickening from asbestos exposure
  • Improving diagnostic accuracy for cardiothoracic conditions
  • Enhancing efficiency in radiology workflows
  • Reducing missed nodules in chest imaging

What Physicians Need to Know

Key Capabilities
DELTAVIEW MODEL (now part of ClearRead Chest suite) utilizes AI algorithms and patented bone and vessel suppression technology to provide an unimpaired view of the chest. It helps radiologists detect, characterize, and visualize pulmonary nodules, pneumothoraces, and coronary artery calcification (CAC). The software electronically compares current and prior chest X-ray images to identify subtle changes, such as emerging or enlarging tumors, and can also be used with Computer-Aided Detection (CAD) to improve early detection of lung disease.
Clinical Utility
The software is designed to improve the early detection of lung cancer and other cardiothoracic conditions, potentially leading to earlier interventions and better patient outcomes. Studies have shown that using Riverain's Temporal Comparison software can lead to an average 12.4% improvement in sensitivity for actionable solitary pulmonary nodules compared to traditional side-by-side X-ray comparisons. It also aims to reduce reading times and ease the cognitive burden on radiologists.
Integration Options
DELTAVIEW MODEL (and the ClearRead Chest suite) is designed to integrate into existing radiology workflows and health IT systems, including PACS, EHR, and reporting systems. Riverain Technologies has collaborated with RapidAI to make its ClearRead Chest suite available through the Rapid Enterprise™ Platform, expanding access and enabling a unified enterprise workflow. The software can be installed on a stand-alone server, virtual machine, or in the cloud.
Compliance Status
DELTAVIEW MODEL (and its successor ClearRead Compare) has received 510(k) clearance from the FDA for its Temporal Comparison software. It also has approval for marketing in the European Union. Riverain's cardiothoracic AI suite is FDA-cleared.
Pricing Model
No specific pricing model or unit of charge is publicly published.
User Experience
The software is designed to be workflow-friendly and uncomplicated, providing an unimpaired view of the chest to improve visualization and reduce cognitive load. It aims to streamline diagnostic workflows and enhance detection accuracy.
Support Quality
Riverain Technologies offers customer care, including FAQs, series recommendations, system requirements, manuals, and customer success resources.
Implementation Complexity
The workflows are described as uncomplicated and easy to understand, whether installed on a stand-alone server, virtual machine, or in the cloud. The software is designed to integrate seamlessly with PACS. Riverain emphasizes ease of installation and follow-up service.
Evidence Base
Riverain Technologies emphasizes its clinical evidence, including peer reviews, reference accounts, and independent studies. Studies have shown improved sensitivity for nodule detection and reduced reading times. The technology has undergone extensive testing to prove its reliability.
Physician Tip

For optimal performance, use thin-slice CT scans (1.0-1.25 mm) with softer reconstruction kernels, and non-contrast exams. Ensure consistent scan characteristics and avoid axial rotation, gaps in slice spacing, and table height changes. While the system can process less-than-ideal data, adhering to these recommendations will yield the best results. The software is particularly helpful in detecting subtle changes in complex areas like the hilum and apices.

DELTAVIEW MODEL (and the ClearRead Chest suite) is designed for seamless integration with existing PACS, EHR, and reporting systems. It is vendor-neutral and can handle a broad range of acquisition protocols. Recent collaborations, such as with RapidAI, further expand its integration capabilities into enterprise imaging platforms, allowing access to Riverain's solutions through unified workflows.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentOn-premise (software solution, integrates with PACS) and Cloud-deployable.
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Pulmonology, Radiology

What the Web Says

Riverain Technologies' DELTAVIEW MODEL, now known as ClearRead +Compare, is a software that electronically compares current and prior chest X-ray images to identify subtle changes that may indicate early-stage lung cancer or other lung diseases. It utilizes bone suppression technology to enhance the visibility of soft tissues by removing ribs and clavicles from the image. The software aims to improve diagnostic accuracy and efficiency for radiologists in detecting and characterizing cardiothoracic diseases.

Overall: Positive

Strengths

  • Improves detection of subtle lung cancers and nodules by accentuating changes over time.
  • Utilizes bone suppression technology for a clearer view of soft tissues in chest X-rays.
  • Reduces radiologist reading times without compromising accuracy.
  • Enhances visualization of small pulmonary nodules (≤2 mm).
  • Integrates with existing PACS and radiology workflows.
  • FDA-cleared and CE marked, used in hundreds of sites worldwide.

Limitations

  • May produce false positives or residuals, especially with incomplete fields of view or non-ideal image series.
  • Optimal performance relies on ideal image conditions (e.g., thin slices, soft reconstruction kernels, minimal artifacts).
  • Concerns about incomplete field of view where vessel suppression may fail in the entire image.
  • Techniques are not specifically intended to assist in finding pulmonary nodules in all cases.
  • Some general skepticism about AI in radiology regarding false positives and the nuance of diagnosis.

Based on reviews from: blackfordanalysis.com, riveraintech.com, sectra.com, rapidai.com, healthairegister.com, aihealthindex.io, auntminnie.com, indeed.com, builtin.com, parikhradiology.com, ajronline.org, aidoc.com, radiologybusiness.com, fiercepharma.com, ai-imaging.org, reddit.com, theimagingwire.com, youtube.com, pulse2.com, g2.com

Last updated: 2026-10-31

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DELTAVIEW MODEL

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

American Journal of Roentgenology (AJR)
Artificial Intelligence (AI) for Lung Nodules, From the AJR Special Series on AI Applications
This article discusses the application of AI algorithms, including Riverain Technologies' DeltaView Model 2.1, for lung nodule detection, characterization, and tracking on chest radiographs and CT scans. It highlights the role of AI in improving early lung cancer detection and addresses challenges in clinical adoption, such as regulatory issues and technical hurdles.
2022-05
PMC (PubMed Central)
Computational healthcare: Present and future perspectives (Review)
This review article traces the history and development of AI-based applications in healthcare, listing DeltaView Model 2.1 by Riverain Technologies as an FDA-approved diagnostic radiology tool from 2011. It discusses the increasing number of FDA-approved AI algorithms in radiology and the challenges and future prospects of AI in medicine.
2021-12
FDA.report
510(k) Premarket Notification - DELTAVIEW MODEL 2.1
This FDA filing indicates that DELTAVIEW MODEL 2.1, developed by Riverain Medical Group, LLC, received 510(k) premarket notification clearance on December 28, 2011, for diagnostic radiology.
2011-12
u56fdu7acbu533bu85acu54c1u98dfu54c1u885bu751fu7814u7a76u6240 u533bu7642u6a5fu5668u90e8 (National Institute of Health Sciences, Medical Devices Department)
u4ee4u548c4u5e74u5ea6 AIu30fbu30e2u30d0u30a4u30ebu7528u30a2u30d7u30eau30b1u30fcu30b7u30e7u30f3u7b49 u6700u5148u7aefu533bu7642u6a5fu5668u8abfu67fbu7b49u4e8bu696d u5831u544au66f8 u4ee4u548c5u5e74
This Japanese report on advanced medical devices, including AI and mobile applications, lists DeltaView Model 2.1 by Riverain Medical Group, LLC, as an FDA-approved radiology device from 2011. It discusses the regulatory landscape for AI/ML-enabled medical devices.
2022-08
HealthAidb
Alternative products to Scope AI - HealthAidb
This software comparison site lists DELTAVIEW MODEL 2.1 from Riverain Medical Group as a diagnostic support tool for clinical care, radiology imaging software, and diagnostic clinical radiology image processing.
unknown
Scribd
Artificial Intelligence and Machine Learning (AIML) - Enabled Medical Devices FDA
This document, which appears to be a list of FDA-approved AI/ML-enabled medical devices, includes DeltaView Model 2.1 by Riverain Technologies, Inc. in the radiology category.
unknown

Videos

Product demos, reviews, and walkthroughs for DELTAVIEW MODEL.

Loading videos...

View all on YouTube

Frequently Asked Questions

The DELTAVIEW MODEL, previously marketed as DeltaView, is a software developed by Riverain Technologies that uses AI to compare current and prior chest X-ray images. It helps identify nodules that may indicate early-stage lung cancer and utilizes bone suppression technology to provide a clearer view of soft tissue. This temporal comparison technology creates a subtraction image to highlight changes that could suggest an emerging or enlarging tumor.
Riverain Technologies' ClearRead solutions, which include the technology previously known as DeltaView, are FDA-cleared. These solutions utilize advanced AI algorithms and unique suppression technology to remove interfering structures like bones and vessels from chest X-rays and CT scans, aiming to improve detection accuracy and decrease reading time. The company also emphasizes using robust and diverse datasets, including synthetic data, to train its algorithms for reliability.
Several AI tools are available for oncology diagnostics and treatment. Some examples include Onc.AI for precision medicine, ArteraAI for multimodal AI, IBM Watson for Oncology for decision support, Tempus for genomic sequencing and precision medicine, and PathAI for digital pathology. Other AI models like Perplexity Sonar Pro, GPT-5.2, Claude 4 Sonnet, and Gemini 3.1 Pro are also used for various oncology tasks such as treatment protocol research, clinical trial matching, and patient communication.
Specific pricing for the DELTAVIEW MODEL (now part of Riverain's ClearRead suite) is not publicly available. Generally, pricing for AI solutions in healthcare can vary significantly based on factors like the specific features, integration requirements, and the scale of deployment within a healthcare system. For other AI tools, some platforms offer tiered subscriptions or enterprise solutions.
Limitations of AI in oncology include the need for high-quality and diverse datasets for training, potential biases in algorithms, and the 'black box' nature of some AI models, which can lead to clinician mistrust. Over-reliance on AI may also diminish clinical expertise. For the DELTAVIEW MODEL specifically, its primary application is in detecting pulmonary nodules from chest imaging, and its utility would be limited to that scope within oncology.
The DELTAVIEW MODEL, as part of Riverain's ClearRead Compare software, is designed to integrate seamlessly with Picture Archiving and Communication Systems (PACS). Riverain Technologies' ClearRead CT has also been integrated through platforms like Aidoc's aiOS™, which helps embed AI technologies into existing clinical workflows, potentially reducing reading times for radiologists.

Related Tools

SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
Paid
CerviCARE AI
NTL Healthcare
OB/GYN AI
CerviCARE AI is an AI-powered cervical cancer screening system that analyzes smartphone images of the cervix to predict findings, aiming for early detection.
Lumonus AI
Lumonus
Clinical Decision Support & Reference
Lumonus AI is an AI-powered software that assists healthcare providers with prescriptions, dosing, and treatment for cancer patients, with a module (Sigma) that suggests treatment protocols based on prior plans for similar patients.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

See all Oncology AI tools →

More from Riverain Technologies

CLEARREAD +CONFIRM
RIVERAIN TECHNOLOGIES
Radiology & Imaging AI
CLEARREAD +CONFIRM is an AI tool by Riverain Technologies that enhances chest X-ray images to improve the visibility and confirmation of lines and tubes, reducing reading time by approximately 19% for radiologists.
Not publicly available
ClearRead CT
RIVERAIN TECHNOLOGIES
Cardiology AI
ClearRead CT is an FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology.
Contact for pricing
ClearRead CT CAC
Riverain Technologies
Cardiology AI
ClearRead CT CAC by Riverain Technologies is an AI-powered software that enables opportunistic screening for coronary artery calcification (CAC) by accurately detecting, quantifying, and reporting Agatston scores from routine, ungated, non-contrast chest CT scans.
Subscription-based, with a saas cost per scan model available.
ClearRead Xray Pneumothorax
Riverain Technologies
Radiology & Imaging AI
ClearRead Xray Pneumothorax is an AI-driven tool by Riverain Technologies that provides triage notification for suspected pneumothorax (5mm or larger) on adult chest X-rays, aiming for early detection and improved radiologist efficiency.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.